

FDA WEEKLY INTELLIGENCE

FDA Intelligence

Coverage: 2026-08-06 – 2026-08-12 (drug approval date basis)

Published: August 16, 2026

Plan: Individual Plan

TABLE OF CONTENTS

This Week at FDA	2
 Asian Company Watch — FDA Activity This Week	3
 Drug Approvals	7
 Medical Devices	8
 Warning Letters	9
 Drug Recalls	10
 FDA Guidance & Regulatory Actions	12
 Upcoming FDA Regulatory Event Calendar	13
—  Weekly Outlook	13
—  This Week's Spotlight (Editor's Picks)	14
—  Changes Since Last Week	15
—  Upcoming FDA Schedule (Official, Not Predicted)	16
—  PDUFA Target Action Dates Disclosed by Sponsors	17
—  Annual Guidance Development Plans (CDER/CBER/CDRH)	21
 Terms of Use & Disclaimer (Individual Plan)	23

Troy-Technical | Auto-generated from openFDA, Federal Register, and FDA.gov public data

FDA Weekly Report — Week 33, 2026

Coverage: 2026-08-06 – 2026-08-12 (drug approval date basis)

Published: August 16, 2026

Note: the reporting period above is based on drug (NDA/BLA) approval dates. FDA typically publishes approvals 1-2 weeks after the decision date. Device data (510(k)/PMA) is published on an even longer lag, so the Medical Devices section covers 2026-07-25 to 2026-07-31.

Note: the issue number ("Week 33, 2026") is the ISO calendar week containing the END of the coverage period above, used only for stable issue numbering — it is not a claim that the coverage period spans that full Monday-Sunday week.

This Week at FDA

The FDA's drug centers were quiet this week, with no new molecular entities or other novel drugs approved, placing the spotlight on medical device innovation which saw one De Novo authorization and one PMA approval. This regulatory calm was offset by a significant quality control issue highlighted in recent data: a Class I recall for JB Chemicals and Pharmaceuticals Ltd's Cetirizine Hydrochloride Tablets due to cross-contamination. The period also saw a notable volume of activity from Asian companies and no significant Warning Letters were identified within the reporting scope.

0

NME Approvals

0

Total Drug Approvals

0

Efficacy Supplements

75

Device Clearances

1

PMA Originals

17

Asian Co. Events

Asian Company Watch — FDA Activity This Week

Coverage: drugs 2026-08-06–2026-08-12, devices 2026-07-25–2026-07-31 (device data is published on a longer lag).

Asian companies with FDA approvals or clearances this week. The highest-priority items below include strategic commentary on what it means for the competitive landscape; the remaining approvals are listed for completeness (full detail for every item is available in the accompanying Excel data set). Country classification is based on ultimate corporate group origin, not necessarily the filing legal entity's place of incorporation (e.g. a US-registered subsidiary of a Japanese parent group is classified as Japanese).

AUROBINDO PHARMA LTD India

TRIAMCINOLONE ACETONIDE

AUROBINDO PHARMA LTD — Generic approval (ANDA) for TRIAMCINOLONE ACETONIDE (TRIAMCINOLONE ACETONIDE).

AUROBINDO PHARMA India

BRIVARACETAM (BRIVARACETAM)

AUROBINDO PHARMA — Generic approval (ANDA) for BRIVARACETAM (BRIVARACETAM).

AUROBINDO PHARMA India

VANCOMYCIN HYDROCHLORIDE

AUROBINDO PHARMA — Generic approval (ANDA) for VANCOMYCIN HYDROCHLORIDE (VANCOMYCIN HYDROCHLORIDE).

LUPIN India

SODIUM ZIRCONIUM CYCLOSILICATE

LUPIN — Generic approval (ANDA) for SODIUM ZIRCONIUM CYCLOSILICATE (SODIUM ZIRCONIUM CYCLOSILICATE).

DR REDDYS India

LORATADINE

DR REDDYS — Generic approval (ANDA) for LORATADINE (LORATADINE AND PSEUDOEPHEDRINE SULFATE).

Intelligence: This approval for a common OTC combination product reinforces Dr. Reddy's position in the high-volume US consumer health and retail pharmacy channel.

Samsung Medison Co., Ltd. South Korea

V8/XV8/XH8/H8/cV8/V8 ONE/XV8 ONE/XH8...

 3rd clearance in 2026 (73 total since 2011) — established filer

 Predicate: K250999 (Samsung Medison Co., Ltd., KR)

South Korea's Samsung Medison received 510(k) clearance for its V-series line of pulsed Doppler diagnostic ultrasound systems.

Intelligence: The clearance covering a wide range of models (V4 through V8) suggests a strategy by Samsung Medison to offer a tiered portfolio of ultrasound systems to different segments of the US healthcare market.

Shanghai United Imaging Healthcare Co., Ltd. China

uMI Panvivo (uMI Panvivo M)

 6th clearance in 2026 (84 total since 2018) — established filer

 Predicate: K241166 (Shanghai United Imaging Healthcare Co., Ltd., CN)

Shanghai United Imaging Healthcare Co., Ltd. received a 510(k) clearance for uMI Panvivo (uMI Panvivo M). FDA classifies this device as: System, Tomography, Computed, Emission.

Nipro Medical Corporation Japan

ELISIO™ -HX

 3rd clearance in 2026 (35 total since 2005) — established filer

 Predicate: K260533 (Nipro Medical Corporation, US)

Japanese company Nipro Medical Corporation received 510(k) clearance for its ELISIO-HX hemodialyzer, a device used in kidney dialysis with an expanded solute removal profile.

Intelligence: Gaining clearance for a hemodialyzer with specific performance claims may help Nipro differentiate its offerings in the competitive US renal care market.

NeuroLogica Corp., a Samsung Company South Korea

BodyTom Elite (NL4000)

 First FDA clearance — new US market entrant

 Predicate: K170238 (Neurologica Corporation, A Subsidiary of Samsung Electronics, US)

NeuroLogica Corp., a US-based Samsung company, received 510(k) clearance for its BodyTom Elite, a portable, full-body computed tomography (CT) scanner.

Intelligence: This clearance for a mobile CT system, filed by its US entity, could support Samsung's strategy to expand its footprint in specialized imaging environments like operating rooms and intensive care units.

T&R BIOFAB CO., Ltd. South Korea

TnR Cranial Implant

 1st clearance in 2026 (2 total since 2023) — established filer

 Predicate: K051093 (Osteopore, Inc., US)

South Korean company T&R BIOFAB CO., Ltd. received 510(k) clearance for its TnR Cranial Implant, a methyl methacrylate device used for cranioplasty procedures.

Intelligence: This clearance provides T&R BIOFAB with a US market entry point for its neurosurgical implant technology, positioning it in the specialized field of cranial reconstruction.

IMGFAX CO., LTD. China

Handheld Ultrasound Scanner

 First FDA clearance — new US market entrant

 Predicate: K241161 (Leltek, Inc., TW)

Chinese firm IMGFAX CO., LTD. obtained 510(k) clearance for its handheld pulsed Doppler ultrasound scanner.

Intelligence: The clearance for a portable, handheld ultrasound device may position IMGFAX to compete in the growing point-of-care ultrasound (POCUS) segment in the US.

Rayence Co., Ltd. South Korea

0909FCE, 0909FCE-HS

 1st clearance in 2026 (39 total since 2011) — established filer Predicate: K240371 (Rayence Co., Ltd., KR)

South Korea's Rayence Co., Ltd. received 510(k) clearance for its solid-state flat-panel digital X-ray imagers.

Intelligence: This clearance adds to Rayence's extensive portfolio of digital radiography detectors, reinforcing its position as a component supplier for the US medical and dental imaging markets.

Suzhou Haowei Medical Technology Co., Ltd. China

UniPearls® Embolic Microspheres

 1st clearance in 2026 (2 total since 2023) — established filer Predicate: K231554 (Suzhou Haowei Medical Technology Co., Ltd., CN)

Suzhou Haowei Medical Technology Co., Ltd. received a 510(k) clearance for UniPearls® Embolic Microspheres. FDA classifies this device as: Device, Vascular, For Promoting Embolization.

Shanghai Hulu Devices Co., Ltd. China

Smart Wireless Stethoscope

 1st clearance in 2026 (3 total since 2018) — established filer Predicate: K220470 (Shanghai Hulu Devices Co., Ltd., CN)

Shanghai Hulu Devices Co., Ltd. from China gained 510(k) clearance for its line of smart wireless electronic stethoscopes.

Intelligence: The introduction of multiple models of a wireless electronic stethoscope could position the company to serve the growing US telehealth and remote patient monitoring markets.

Olympus Medical Systems Corporation Japan

EVIS EUS Ultrasound Gastrointestinal Videoscope

 3rd clearance in 2026 (83 total since 2004) — established filer Predicate: K251859 (Olympus Medical Systems Corporation, JP)

Olympus Medical Systems Corporation received a 510(k) clearance for EVIS EUS Ultrasound Gastrointestinal Videoscope (Olympus GF-UE190). FDA classifies this device as: Endoscopic Ultrasound System, Gastroenterology-Urology.

Samsung Electronics Co., Ltd. **South Korea**

Hearing Aid Feature

 2nd clearance in 2026 (42 total since 2013) — established filer

Samsung received 510(k) clearance for air-conduction hearing aid software, a feature that assists with hearing.

Xiamen High Top Electronic Technology Co., Ltd. **China**

Air Compression Massager (HY-1165)

 1st clearance in 2026 (2 total since 2022) — established filer

 Predicate: K182668 (Rapid Reboot Recovery Products, LLC, US)

Xiamen High Top received 510(k) clearance for an air compression massager, a powered inflatable tube device.

 Drug Approvals

0 new drug approvals this week (0 NMEs). 0 efficacy supplements. 9 generics (ANDA).

 Medical Devices

Coverage period for this section: **2026-07-25 to 2026-07-31** — FDA publishes device decisions later than drug approvals, so this differs from the report period (2026-08-06 to 2026-08-12) and is anchored to the latest available device data.

510(k) clearances: **74** (plus 1 separate De Novo authorization). PMA (premarket approval) totals **61**, broken down below — Original/Panel-Track represent new or significant changes.

PMA Original: **1** | Panel-Track: **0** | 30-Day Notice: **48** | Other: **12**

PMA Approvals

PGDx elio tissue complete CDx

Personal Genome Diagnostics, Inc.

Next generation sequencing oncology panel for detecting somatic or germline variants.

510(k) / De Novo Clearances (most recent 10)

Device	Applicant	Date
Air Compression Massager (HY-1165) FDA classifies this device as: Massager, Powered Inflatable Tube.	Xiamen High Top Electronic Technology Co., Ltd.	2026-07-27
V8/XV8/XH8/H8/cV8/V8 ONE/XV8 ONE/XH8... FDA classifies this device as: System, Imaging, Pulsed Doppler, Ultrasonic.	Samsung Medison Co., Ltd.	2026-07-28
uMI Panvivo (uMI Panvivo M) FDA classifies this device as: System, Tomography, Computed, Emission.	Shanghai United Imaging Healthcare Co., Ltd.	2026-07-28
ELISIO™-HX A hemodialyzer with expanded solute removal profile for treating kidney failure.	Nipro Medical Corporation	2026-07-28
CaRi-Heart De Novo Caristo Diagnostics, Ltd. received FDA clearance for this device.	Caristo Diagnostics, Ltd.	2026-07-28
BodyTom Elite (NL4000) FDA classifies this device as: System, X-Ray, Tomography, Computed.	NeuroLogica Corp., a Samsung Company	2026-07-28
TnR Cranial Implant FDA classifies this device as: Methyl Methacrylate For Cranioplasty.	T&R BIOFAB CO., Ltd.	2026-07-30

Handheld Ultrasound Scanner FDA classifies this device as: System, Imaging, Pulsed Doppler, Ultrasonic.	IMGFAX CO., LTD.	2026-07-30
0909FCE, 0909FCE-HS FDA classifies this device as: Solid State X-Ray Imager (Flat Panel/Digital Imager).	Rayence Co., Ltd.	2026-07-31
UniPearls® Embolic Microspheres FDA classifies this device as: Device, Vascular, For Promoting Embolization.	Suzhou Haowei Medical Technology Co., Ltd.	2026-07-31

* Full 75-item 510(k)/De Novo dataset available in the Excel file attached to this issue.

 Warning Letters

Total this week: 0 | Significant (manufacturing/GMP, or not classifiable as unapproved/labeling-only): 0 | Unapproved/labeling ONLY (no manufacturing-quality finding; mostly supplement/personal-import cases): 0

Drug Recalls

Drug Recalls (Top Items) (showing 10 rows covering 41 of 49 total recalls in the latest available recall data (2026-07-22 to 2026-08-05); recalls from the same company for the same reason are grouped into one row. Full list available in the accompanying Excel data file.)

Note: "Recalling Firm" is the firm that filed the recall with the FDA (openFDA's recalling_firm field) — it is not necessarily the actual manufacturer, which may differ from the firm named in the Product column.

Recalling Firm	Product	Reason	Class
JB Chemicals and Pharmaceuticals Ltd	Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.	Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.	Class I
Rohto-Mentholatum (Vietnam) Co., Ltd.	Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 90, 0.2%), Sterile 0.4 FL OZ (13 mL), Distributed by: The Mentholatum Company, Orchard Park, NY 14127, Made in Vietnam, UPC 310742011012, NDC 10742-8158-1 (+7 similar recalls, same company & reason, grouped)	Lack of Assurance of Sterility	Class II
Chiesi USA, Inc.	CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single Use Vials, Rx Only, Manufactured for: Chiesi USA, Inc., Cary, NC 27518, by Fresenius Kabi, Graz, Austria, NDC 10122-611-10.	Lack of Assurance of Sterility	Class II
CareFusion 213, LLC	BD Chloraprep Clear, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol), 60 x 1 mL applicators/carton, 0.03fl oz (1 mL) each, STERILE SOLUTION, CareFusion 123, LLC, El Paso, TX, subsidiary of Beckton, Dickson and Co. NDC 54365-400-31	Lack of Assurance of Sterility: Affected product may exhibit an open or incomplete seal on the packaging of the applicator	Class II
Glenmark Pharmaceuticals Inc., USA	Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, Distributed by: Glenmark Pharmaceuticals Inc., USA, Elmwood Park, NJ 07407, NDC 68462-626-52.	CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.	Class II

Major Pharmaceuticals	Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 10 Tablets (10 x 1) unit dose blisters per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. Distributed by Cardinal Health, Dublin, OH 43017. NDC Bag: 55154-3560-0; NDC Blister: 0904-6951-61 (+11 similar recalls, same company & reason, grouped)	Subpotent Drug	Class II
Bell Pharmaceuticals, Inc	QC Quality Choice, Carbamide Peroxide, 6.5%, 0.5 FL. OZ. (15 mL) a) Washer Bulb included (NDC 63868-026-15); b) 1 bottle (NDC 63868-027-16), Distributed by C.D.M.A., Inc., 43157 W. Nine Mile, Novi, MI 48376. (+10 similar recalls, same company & reason, grouped)	SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).	Class II
Padagis US LLC	Nystatin Cream USP, (100, 000 USP Nystatin Units), NET WT 15 g, Rx only, 15 g tube, Manufactured by Padagis, Yeruham, Israel, NDC 45802-059-35	Subpotent Drug: Low out of specification assay results performed during long-term stability testing.	Class II
Fresenius Kabi USA, LLC	Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05 (+3 similar recalls, same company & reason, grouped)	Presence of Particulate Matter: Hair was found in products	Class II
MYLAN PHARMACEUTICALS INC	Mycophenolate Mofetil for Injection USP, 500 mg/Vial, Single Dose Vial, 4 vials per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV, 26505 USA, Made in India, NDC 67457-386-00.	Presence of precipitate	Class II

 FDA Guidance & Regulatory Actions

13 FDA regulatory documents this week.

[Determination That ANSAID \(Flurbiprofen\) Tablets, 50 Milligrams and 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness](#) (2026-08-14 • Notice)

This notice determines that ANSAID (Flurbiprofen) tablets were not withdrawn for safety or effectiveness reasons, affecting generic drug manufacturers seeking bioequivalent versions.

[Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments](#) (2026-08-14 • Notice)

This notice announces a public meeting and requests comments on the reauthorization of the Prescription Drug User Fee Act (PDUFA). It affects pharmaceutical companies and stakeholders in prescription drug development.

[Determination That LASIX \(Furosemide\) Tablets, 20 Milligrams, 40 Milligrams, and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness](#) (2026-08-14 • Notice)

This notice determines that LASIX (Furosemide) tablets were not withdrawn for safety or effectiveness reasons, affecting generic drug manufacturers seeking bioequivalent versions.

[Container Closure Systems for Human Drugs and Biological Products; Draft Guidance for Industry; Availability](#) (2026-08-14 • Notice)

This notice announces the availability of draft guidance on container closure systems for human drugs and biological products. It affects pharmaceutical and biologics manufacturers.

[Kremers Urban Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Withdraw Approval of an Abbreviated New Drug Application for Extended-Release Methylphenidate Tablets](#) (2026-08-13 • Notice)

This notice grants a hearing request regarding a proposal to withdraw approval of an Abbreviated New Drug Application for extended-release methylphenidate tablets. It affects Kremers Urban Pharmaceuticals.

[Guide To Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce; Guidance for Industry; Availability](#) (2026-08-12 • Rule)

This rule announces the availability of guidance to minimize biological hazards in ready-to-eat fresh-cut produce. It affects the produce industry, including growers, processors, and distributors.

[Reauthorization of the Generic Drug User Fee Amendments; Public Meeting; Request for Comments](#) (2026-08-11 • Notice)

This notice announces a public meeting and requests comments on the reauthorization of the Generic Drug User Fee Amendments (GDUFA). It affects generic drug manufacturers and stakeholders.

[Substances Generally Recognized as Safe](#) (2026-08-11 • Proposed Rule)

This proposed rule addresses criteria and procedures for substances generally recognized as safe (GRAS). It affects food manufacturers and ingredient suppliers.

[Determination That OZOBAX \(Baclofen\) Oral Solution, 5 Milligrams/5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness](#) (2026-08-10 • Notice)

This notice determines that OZOBAX (Baclofen) oral solution was not withdrawn for safety or effectiveness reasons, affecting generic drug manufacturers seeking bioequivalent versions.

[Determination of Regulatory Review Period for Purposes of Patent Extension; BRINSUPRI](#) (2026-08-10 • Notice)

This notice establishes the regulatory review period FDA uses to calculate a potential patent-term extension for BRINSUPRI, to be decided by the USPTO. It affects the patent holder.

[Determination of Regulatory Review Period for Purposes of Patent Extension; DAYVIGO](#) (2026-08-10 • Notice)

This notice establishes the regulatory review period FDA uses to calculate a potential patent-term extension for DAYVIGO, to be decided by the USPTO. It affects the patent holder.

[Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-GRAIL, Inc. Galleri](#) (2026-08-10 • Notice)

This notice announces a meeting of the Molecular and Clinical Genetics Panel and requests comments on GRAIL, Inc.'s Galleri device. It affects medical device manufacturers in genetic diagnostics.

[Radiology Devices; Reclassification of Digital Breast Tomosynthesis System](#) (2026-08-10 • Proposed Rule)

This proposed rule reclassifies digital breast tomosynthesis systems. It affects manufacturers of radiology devices, specifically those producing breast imaging equipment.

 Upcoming FDA Regulatory Event Calendar



Weekly Outlook

This week's notable events include Deramiocel (2026-08-22) and Zilganerssen (2026-09-22). In the Guidance Agenda, CDER's Generics category has the most items (24).

This text is generated mechanically from existing aggregate data (priority, countdown, category counts). It contains no forecasts or speculation.

★ This Week's Spotlight (Editor's Picks)

Selected mechanically by priority tier and proximity (days until event) — the notable items for this week.

Date	Priority	Event	Type
2026-08-22 in 6d	★★★★★	Deramiocel	PDUFA
2026-09-22 in 37d	★★★★★	Zilganersen	PDUFA
2026-09-26 in 41d	★★★★★	zilurgisertib	PDUFA
2026-09-30 in 45d	★★★★★	apitegromab	PDUFA
2026-08-25 in 9d	★★★★☆	zanidatamab	PDUFA

**Changes Since Last Week**

Category	Count
New (PDUFA 33 / AdCom 2 / Guidance 0)	35
Postponed / rescheduled	0
Removed / withdrawn	27

New this week (PDUFA / AdCom) (showing top 10 of 35)

- [PDUFA] Deramiocele (2026-08-22)
- [PDUFA] zanidatamab (2026-08-25)
- [PDUFA] zanidatamab (2026-08-25)
- [PDUFA] Zilganerser (2026-09-22)
- [PDUFA] zilurgisertib (2026-09-26)
- [PDUFA] apitegromab (2026-09-30)
- [PDUFA] Bepirovirsin (2026-10-26)
- [PDUFA] INO-3107 (2026-10-30)
- [PDUFA] ivonescimab (2026-11-14)
- [PDUFA] BBP-418 (2026-11-27)

Removed / withdrawn (showing top 10 of 27)

- [AdCom] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food and Drug Administration Advisory Committees
- [PDUFA] Deramiocele
- [PDUFA] Deramiocele
- [PDUFA] zanidatamab
- [PDUFA] zanidatamab
- [PDUFA] Zilganerser
- [PDUFA] zilurgisertib
- [PDUFA] apitegromab
- [PDUFA] Bepirovirsin
- [PDUFA] ivonescimab



Upcoming FDA Schedule (Official, Not Predicted)

This section contains no forecasts. It lists only officially announced FDA events, each linked to its primary source.

Date	Priority	Advisory Committee / Topic	Product / Company	Source
2026-09-23 in 38d	★★★★☆	Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-GRAIL, Inc. Galleri	—	Federal Register
2026-10-16 in 61d	★★★★☆	Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer	—	Federal Register

**PDUFA Target Action Dates Disclosed by Sponsors**

This list is compiled from information disclosed by companies in SEC filings, official press releases, and investor materials. It is not a comprehensive official schedule published by FDA. Dates may change, be delayed, or be withdrawn. Always verify against the primary source linked below before making investment, regulatory, or business decisions.

Confirmed (exact date disclosed)

Target Action Date	Priority	Product	Company	Indication	Source
2026-08-22 in 6d	★★★★★	Deramiciel	CAPRICOR THERAPEUTICS, INC.	cardiomyopathy in patients with Duchenne muscular dystrophy	SEC 8-K
2026-08-25 in 9d	★★★★☆	zanidatamab	Jazz Pharmaceuticals plc	first-line (1L) gastroesophageal adenocarcinoma (GEA)	SEC 8-K (Press Release)
2026-08-25 in 9d	★★★★☆	zanidatamab	Zymeworks Inc.	first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA)	SEC 8-K (Press Release)
2026-09-22 in 37d	★★★★★	Zilganersen	Ionis Pharmaceuticals, Inc.	Alexander disease (AxD)	SEC 8-K (Press Release)
2026-09-26 in 41d	★★★★★	zilurgisertib	Mirum Pharmaceuticals, Inc.	fibrodysplasia ossificans progressiva (FOP)	SEC 8-K (Press Release)
2026-09-30 in 45d	★★★★★	apitegromab	Scholar Rock	spinal muscular atrophy (SMA)	SEC 8-K (Press Release)
2026-10-26 in 71d	★★★★★	Bepirovirsen	IONIS PHARMACEUTICALS INC (IONS) (CIK 0000874015)	chronic hepatitis B (CHB)	SEC 8-K (Press Release)
2026-10-30 in 75d	★★★★★	INO-3107	INOVIO PHARMACEUTICALS, INC.	Recurrent Respiratory Papillomatosis (RRP)	SEC 8-K (Press Release)

2026-11-14 in 90d	★★★★★	ivonescimab	Summit Therapeutics Inc.	EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR TKI	SEC 8-K (Press Re
2026-11-27 in 103d	★★★★★	BBP-418	BridgeBio Pharma, Inc.	LGMD2I/R9	SEC 8-K (Press Re
2026-11-27 in 103d	★★★★★	—	BridgeBio Disclosed in BridgeBio Pharma, Inc.'s filing	—	SEC 8-K (Press Re
2026-11-30 in 106d	★★★★★	Povetacicept	Vertex	immunoglobulin A nephropathy (IgAN)	SEC 8-K (Press Re
2026-12-03 in 109d	★★★★★	zanzalintinib	Exelixis, Inc.	metastatic colorectal cancer	SEC 8-K (Press Re
2026-12-12 in 118d	★★★★★	Quimilza TM	Vanda Pharmaceuticals Inc.	Generalized Pustular Psoriasis (GPP)	SEC 8-K (Press Re
2026-12-27 in 133d	★★★★★	relutrigine	Praxis Precision Medicines, Inc.	SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)	SEC 8-K (Press Re
2026-12-30 in 136d	★★★★★	bezuclastinib	Cogent Biosciences, Inc.	NonAdvSM	SEC 8-K (Press Re
2027-01-06 in 143d	★★★★☆	ANKTIVA	ImmunityBio, Inc.	BCG- unresponsive NMIBC with papillary disease without CIS	SEC 8-K (Press Re
2027-01-21 in 158d	★★★★★	z-rostudirsen	Dyne Therapeutics, Inc.	Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping	SEC 8-K (Press Re
2027-01-29 in 166d	★★★★★	ulixacaltamide	Praxis Precision Medicines, Inc.	Essential Tremor	SEC 8-K (Press Re

2027-02-23 in 191d	★★★★☆	ZORYVE cream 0.05%	Arcutis Biotherapeutics, Inc.	mild to moderate atopic dermatitis in infants aged 3 to 24 months	SEC 8-K (Press Release)
2027-02-27 in 195d	★★★★★	zipalertinib	Cullinan Therapeutics, Inc. (CGEM) (CIK 0001789972)	locally advanced or metastatic EGFR ex20ins NSCLC whose disease has progressed on or after platinum- based chemotherapy, with or without amivantamab	SEC 8-K (Press Release)
2027-02-28 in 196d	★★★★☆	VOXZOGO	BioMarin Pharmaceutical Inc.	achondroplasia	SEC 8-K (Press Release)
2027-04-01 in 228d	★★★★★	Pitolisant GR	Harmony Biosciences Holdings, Inc.	narcolepsy	SEC 8-K (Press Release)
2027-04-28 in 255d	★★★★★	Varegacestat	Immunome, Inc.	desmoid tumors	SEC 8-K (Press Release)
2027-05-01 in 258d	★★★★★	AXS-12	Axsome Therapeutics, Inc.	cataplexy in narcolepsy	SEC 8-K (Press Release)
2027-05-08 in 265d	★★★★★	encaleret	BridgeBio Pharma, Inc.	ADH1	SEC 8-K (Press Release)
2027-05-27 in 284d	★★★★★	obexelimab	Zenas BioPharma, Inc.	Immunoglobulin G4-Related Disease (IgG4- RD)	SEC 8-K (Press Release)

Partially disclosed (quarter / month / half-year only)

Expected Timing	Priority	Product	Company	Source
August 2026	★★★★★	rusfertide	Protagonist Therapeutics	SEC 8-K (Press Release)
September 2026	★★★★★	Ameluz	Biofrontera Inc.	SEC 8-K (Press Release)
2028 (timing TBD)	★★★★★	Pitolisant HD	Harmony Biosciences Holdings, Inc.	SEC 8-K (Press Release)
2028 (timing TBD)	★★★★★	WAKIX (pitolisant)	Harmony Biosciences Holdings, Inc.	SEC 8-K (Press Release)

2028 (timing TBD)	★★★★★	EPX-100 (clemizole hydrochloride)	Harmony Biosciences Holdings, Inc.	SEC 8-K (Press Release)
2028 (timing TBD)	★★★★★	Pitolisant	Harmony Biosciences	SEC 8-K (Press Release)

Annual Guidance Development Plans (CDER/CBER/CDRH)

Each center publishes an annual list of guidance topics it is considering. Individual items have no committed publication date, and FDA does not guarantee every listed topic will be issued.

CDER (CY2026) — 85 items • [Official page](#)

By category: Generics (24), Pharmaceutical Quality/CMC (10), Clinical/Medical (9), Administrative/Procedural (8), Compounding (8), Biosimilars (6) and more

- Drug and Device Manufacture Communications with Payors, Formulary Committees, and Small Entities - Questions and Answers; Revised Draft
- Engaging with FDA to Discuss the Use of Digital Health Technologies in Clinical Investigations of Drug and Biological Products
- Exclusivity for First Interchangeable Biosimilar Biological Products
- Expedited Programs: Fast Track, Breakthrough Therapy, and Priority Review
- NDC Creation, Assignment, Listing and Appropriate Use for Human Drugs, Including Biological Products
- Priority Review Voucher Programs

+79 more (see official page for the full list)

CBER (CY2026) — 35 items • [Official page](#)

By category: Therapeutic Products (19), Vaccines and Allergens (9), Blood and Blood Components (5), Other (2)

- Considerations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method; Guidance for Industry
- Collection of Platelets by Automated Methods; Draft Guidance for Industry
- Recommendations for Testing Blood Donations for Hepatitis B Virus; Guidance for Industry
- Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria; Guidance for Industry
- Recommendations for Testing Blood Donations for Human T-lymphotropic Viruses I and II; Draft Guidance for Industry
- Frequently Asked Questions - Cell and Gene Therapy Products; Guidance for Industry

+29 more (see official page for the full list)

CDRH (FY2026) — 20 items • [Official page](#)

By category: |UC (9), |A (7), |B (3), ||A (1)

- Validation of Diagnostic Tests for Emerging Pathogens following a Declaration and Determination under Section 564
- Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices
- Predetermined Change Control Plans for Medical Devices
- Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle
- Enforcement Discretion Policy for Premarket and Other Requirements for NIOSH-Approved Air Purifying Respirators
- Menstrual Products - Labeling and Performance Testing Recommendations

+14 more (see official page for the full list)

Priority (★) criteria

- ★★★★★ Major approval decision / highest market impact
- ★★★★☆ AdCom tied to a specific product / initial BLA-NDA approval-related
- ★★★☆☆ Advisory Committee (general business, not tied to a specific product)
- ★★☆☆☆ Committee administration / procedural notice
- ★☆☆☆☆ Administrative/procedural public meeting

FDA Weekly Intelligence

Data sources: openFDA • Federal Register • FDA.gov official publications
Auto-generated • 2026-08-16 10:39 JST

Generation policy: every claim is grounded in primary sources (FDA official databases and verbatim approval-letter text) — the AI is not permitted to invent facts • cross-checked against multiple public databases for consistency • key items are verified against the actual FDA approval letter before being described.

For informational purposes only. Not legal, medical, or investment advice. See Terms of Use on final page.

© 2026 Troy Technical. All rights reserved.

 **This report is licensed to the registered individual subscriber only. Forwarding, copying, or sharing this report or the attached Excel file is strictly prohibited.**

Terms of Use & Disclaimer (Individual Plan)

Thank you for subscribing to **FDA Weekly Intelligence**. Please read the following terms carefully before using this report and any accompanying files.

1. Data Sources & AI-Assisted Generation

All data and information published in this report is sourced from official U.S. government publications, including the U.S. Food and Drug Administration (FDA) official website, the Federal Register, and the openFDA database.

To extract timely and actionable intelligence from large volumes of regulatory data, this report uses advanced generative AI (large language models) for data processing, summarization, and strategic commentary generation.

2. Accuracy & AI Hallucination Disclaimer

While we apply quality review processes after AI-assisted generation to minimize errors, the nature of machine learning models means that translation nuances, contextual misinterpretations, or inaccuracies may occasionally appear. We do not guarantee the 100% accuracy, completeness, timeliness, or fitness for a particular purpose of any information provided.

For decisions requiring verified regulatory information, always refer to the original English-language source documents published by the FDA.

3. No Professional Advice

This report provides general market intelligence for informational purposes only. It does not constitute and should not be relied upon as:

- **Regulatory or legal advice:** Not a substitute for qualified legal or regulatory counsel regarding FDA submissions, compliance, or enforcement matters.
- **Investment advice:** Not a recommendation to buy, sell, or hold any security, or to pursue any M&A or licensing transaction.
- **Medical advice:** Not intended to guide clinical decisions by healthcare professionals or patients.
- **Drug or device recommendation:** This report summarizes FDA's publicly announced approvals, clearances, warning letters, and other enforcement actions. It does not recommend, endorse, or make any representation regarding the efficacy, safety, or superiority of any specific drug or medical device.

The publisher accepts no liability for any direct or indirect loss, including lost profits, business interruption, or consequential damages, arising from reliance on the information in this report. All decisions based on this report are made at the reader's own risk.

4. Copyright, Permitted Use & Sharing Policy (Individual Plan)

All intellectual property rights in this report and accompanying data files are owned by the publisher. To protect the value of this service, the following usage rules apply:

Permitted Use (Individual Subscriber)

Access to this report is granted solely to the registered individual subscriber. You may use data and insights from this report in your own professional work, including internal presentations, memos, and reports, provided you do not reproduce the report in its entirety.

Prohibited Use (Sharing & Redistribution)

Forwarding or distributing this report (HTML, PDF, or Excel) to colleagues, clients, or any third party is strictly prohibited. Sharing login credentials or account access with others is also prohibited. Publishing any portion on websites or social media, or reselling this content, is not permitted. Violations may result in immediate termination of service and claims for damages.

5. Subscription, Auto-Renewal & Refund Policy

Subscription & Auto-Renewal Disclosure: This is a recurring subscription service. Your subscription will automatically renew at the end of each billing period, and your payment method will be charged automatically unless you cancel before the renewal date. You will receive a reminder email prior to each renewal. To cancel, log in to your membership account at troy-intelligence.com/membership-account/ and cancel before the next billing date. Cancellation stops future charges but does not entitle you to a refund for the current period.

Refund Policy: Due to the digital nature of this product, refunds are not available once a report has been delivered or a billing period has commenced. If you believe you were charged in error, please contact us within 7 days at info@troy-technical.jp and we will review your case.

6. Privacy & GDPR Compliance

We collect and process only the personal data necessary to deliver this service (name, email address, and billing information). Your data is processed by our membership and payment platform (troy-intelligence.com, powered by WordPress with Stripe as the payment processor) in accordance with their respective privacy policies. We do not sell or share your personal data with third parties for marketing purposes.

If you are a resident of the European Economic Area (EEA) or the United Kingdom, you have the following rights under the General Data Protection Regulation (GDPR) and applicable UK data protection law:

- **Right of access:** You may request a copy of the personal data we hold about you.
- **Right to rectification:** You may request correction of inaccurate personal data.
- **Right to erasure:** You may request deletion of your personal data, subject to our legal obligations to retain certain records.
- **Right to object / restrict processing:** You may object to or request restriction of processing of your personal data in certain circumstances.
- **Right to data portability:** You may request a machine-readable copy of your data.

To exercise any of these rights, please contact us at info@troy-technical.jp. We will respond within 30 days. You also have the right to lodge a complaint with your local data protection authority.

The legal basis for processing your personal data is the performance of a contract (delivery of the subscription service you have purchased).

7. Limitation of Liability

To the maximum extent permitted by applicable law, the publisher's total liability to you for any claim arising out of or in connection with this service shall not exceed the total subscription fees paid by you in the three (3) months preceding the claim. In no event shall the publisher be liable for any indirect, incidental, special, consequential, or punitive damages, including but not limited to loss of profits, loss of data, or business interruption, even if advised of the possibility of such damages.

8. Dispute Resolution & Governing Law

These Terms are governed by the laws of Japan, without regard to its conflict of law provisions. Any dispute, controversy, or claim arising out of or relating to these Terms or the service shall first be attempted to be resolved through good-faith negotiation. If not resolved within 30 days, the dispute shall be finally settled by binding arbitration administered by the Japan Commercial Arbitration Association (JCAA) under its Commercial Arbitration Rules. The arbitration shall be conducted in English, in Tokyo, Japan. The arbitral award shall be final and binding on both parties.

Nothing in this section shall prevent either party from seeking urgent injunctive or other equitable relief from a court of competent jurisdiction to prevent irreparable harm.

9. Service Continuity Statement

The core functionality of this service relies heavily on third-party generative AI (large language model) services. If the supply policies, pricing structure, or terms of use of such third-party services change materially, or if such services are discontinued or become unavailable, such that the quality, cost structure, or operation of this service can no longer be reasonably maintained, the publisher reserves the right to **suspend or terminate this service**. If termination becomes necessary, subscribers will be notified by email at least 30 days in advance, and any fees already collected for undelivered subscription periods will be refunded on a pro-rata basis. The publisher will use reasonable efforts to maintain service stability but does not guarantee that this service will continue indefinitely.

10. Changes to These Terms

We reserve the right to update these Terms at any time. Material changes will be notified to subscribers by email at least 14 days before taking effect. Continued use of the service after the effective date of any changes constitutes your acceptance of the revised Terms.

© 2026 Troy Technical. All rights reserved. / Publisher: Troy Technical / Last updated: June 28, 2026 / Contact: info@troy-technical.jp